PMID- 31242784
OWN - NLM
STAT- MEDLINE
DCOM- 20190904
LR  - 20190904
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 18
IP  - 9
DP  - 2019 Sep
TI  - Safety considerations in the psychopharmacology of pediatric bipolar disorder.
PG  - 777-794
LID - 10.1080/14740338.2019.1637416 [doi]
AB  - Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often 
      requires life-long psychopharmacological management. Several pharmacological 
      agents are approved by the US FDA for the treatment of pediatric BPD. However, 
      each medication may cause adverse events (AEs). Provider awareness of AE profiles 
      of common pharmacologic agents would serve to better inform patients and families 
      in evaluating and selecting between treatment options. Areas covered: This review 
      focuses on medications that, in our clinical experience, are commonly prescribed 
      for youth with BPD and were evaluated in prospective clinical trials for the 
      treatment of pediatric BPD. This paper highlights acute and long-term AEs 
      described in these studies. Expert opinion: Most medications increase risk of AEs 
      in youth with BPD. Treatment with lithium may lead to thyrotropin elevations, but 
      generally does not cause significant weight gain. Divalproex may lead to weight 
      gain; however, this finding was not consistent in comparison studies with 
      lithium. Olanzapine, risperidone, quetiapine, and asenapine are associated with 
      metabolic abnormalities and weight gain. Studies of ziprasidone, aripiprazole and 
      lurasidone do not suggest significant metabolic AEs. More studies are needed to 
      assess efficacy and safety of medications in managing pediatric BPD. Special 
      focus on long-term maintenance trials is required to further identify long-term 
      AEs in this population.
FAU - Sun, Amanda Y
AU  - Sun AY
AD  - a Department of Psychiatry and Behavioral Sciences, Division of Child and 
      Adolescent Psychiatry, Johns Hopkins University School of Medicine , Baltimore , 
      USA.
FAU - Woods, Steven
AU  - Woods S
AD  - a Department of Psychiatry and Behavioral Sciences, Division of Child and 
      Adolescent Psychiatry, Johns Hopkins University School of Medicine , Baltimore , 
      USA.
FAU - Findling, Robert L
AU  - Findling RL
AD  - a Department of Psychiatry and Behavioral Sciences, Division of Child and 
      Adolescent Psychiatry, Johns Hopkins University School of Medicine , Baltimore , 
      USA.
FAU - Stepanova, Ekaterina
AU  - Stepanova E
AD  - a Department of Psychiatry and Behavioral Sciences, Division of Child and 
      Adolescent Psychiatry, Johns Hopkins University School of Medicine , Baltimore , 
      USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20190711
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antipsychotic Agents)
RN  - 9002-71-5 (Thyrotropin)
SB  - IM
MH  - Adolescent
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Bipolar Disorder/*drug therapy
MH  - Child
MH  - Humans
MH  - Thyrotropin/metabolism
MH  - Time Factors
MH  - Weight Gain/*drug effects
OTO - NOTNLM
OT  - Safety
OT  - adverse events
OT  - anticonvulsants
OT  - antipsychotics
OT  - bipolar disorder
OT  - lithium
OT  - pediatric
OT  - treatment
EDAT- 2019/06/28 06:00
MHDA- 2019/09/05 06:00
CRDT- 2019/06/28 06:00
PHST- 2019/06/28 06:00 [pubmed]
PHST- 2019/09/05 06:00 [medline]
PHST- 2019/06/28 06:00 [entrez]
AID - 10.1080/14740338.2019.1637416 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2019 Sep;18(9):777-794. doi: 10.1080/14740338.2019.1637416. 
      Epub 2019 Jul 11.